Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > NanoViricides Presents FluCide™ Animal Study Data At Influenza Congress

Abstract:
Now Improved Substantially And Vastly Superior To Current Treatment

NanoViricides Presents FluCide™ Animal Study Data At Influenza Congress

West Haven, CT | Posted on November 24th, 2009

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that Dr. Eugene Seymour, MD MPH, CEO of the Company, presented lifetime data from the recent FluCide™ animal study on November 19th at the Influenza Congress USA 2009 in Washington, DC.

These data clearly established that the new version of FluCide™ is superior to the older version. The data also showed extremely large survival lifetime improvement compared to an extended therapy using oseltamivir (Tamiflu® Roche).

Separately, Dr. Anil R. Diwan, President of the Company, presented a talk on November 18th at the Nano and Clean Tech 2009 Conference (www.chemshow.com/includes/nano.pdf) in New York City, held in conjunction and partnership with the Chem Show 2009.

Dr. Diwan gave a description of the nanomedicine technology on which the Company's product platform is based. He then went on to discuss the successful development of several drug candidates in a relatively short timeframe and with very small R&D expenditures that NanoViricides Inc. has been able to achieve. "Our achievements have clearly demonstrated that we can develop drug candidates against new virus targets very quickly," he said. He explained that the multi-point binding of a nanoviricide™, enabled by the underlying TheraCour® polymer, results in a nanoscale "velcro" or zipper-like effect. This allows the Company to employ virus-binding ligands with relatively low affinities successfully. "Other drug development approaches require discovery of antibodies or chemicals with very high affinities, sub-micromolar or better, which takes a lot of time and money," he said, adding, "In contrast, our technology allows us to use mimics of the natural and conserved binding sites of the viruses. This allows rapid development. Also, it means that a virus is far less likely to escape a nanoviricide compared to its escape rate against a highly specific drug discovered using a conventional methodology."

The recent animal study of FluCide was conducted using the same total lethality protocol employed in previous influenza studies by the Company. The new version of FluCide drug candidate extended the lifespan of lethally infected mice to 334±11 hrs (or 14 days) on average. In contrast, mice treated with an extended oseltamivir protocol survived for 193±3 hrs (or 8 days) on average. Control infected mice survived for only 121±2 hrs (or 5 days). FluCide was given as an IV injection, on alternate days, for five treatments. Oseltamivir was given as oral, twice daily, each at 20mg/kg through life (or 14 treatments). Previously, oseltamivir given using the customary protocol of oral, twice daily, each at 20mg/kg for 4 days (8 treatments), has produced a survival time of 151±1 hrs (or 6.3 days) in this model. Several additional parameters have been evaluated in this study. The Company expects to analyze the data from these additional parameters as they are received in the near future.

The Company believes that the lifetime data demonstrate an unquestionable superiority of the FluCide drug candidate compared to current drugs, and establish it as a viable therapy against influenza. We believe that FluCide is likely the most effective drug candidate in development against influenza, based on these results.

The studies were conducted by Dr. Krishna Menon, PhD, VMD, MRCS, at KARD Scientific, MA. One million virus particles of Influenza A Strain A/WS/33 (H1N1) were aspirated directly into the lungs of mice. A repeat "booster" infection was performed at 22 hrs. This is a highly lethal model, allowing the survival lifetimes to be directly used for rank ordering of efficacy of drug candidates.

The Company has previously shown that a previous version of the FluCide drug candidate was highly effective against two different clades of the H5N1 bird flu virus, in addition to being highly effective against H1N1 in the mouse model. The Company has recently improved the FluCide drug candidate, creating what it believes to be a single drug candidate against all forms of influenza. The Company believes that the data we presented at the Influenza Conference establish this pan-influenza drug candidate as a leading anti-influenza drug in development.

####

About NanoViricides
We have assembled a world class team to lead us to success. We have brought together highly experienced individuals with strong expertise in their respective areas. Our team possesses the combined expertise of having performed research, development, and regulatory processing for over 25 drugs, of which 10 are approved and the rest are at various advanced clinical stages, at the team members' previous affiliations. Our team is also highly innovative, and boasts pioneering research in varied areas that are at the fore-fronts of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes, and gene therapy.

For more information, please click here

Contacts:

Copyright © medicalnewstoday.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Products

Toronto-based Environmental Technology Pioneer Green Earth Nano Science Expands in EU February 6th, 2015

DELSEY by Philippe Starck DELSEY Launches New Collection by Philippe Starck February 4th, 2015

NEI introduces NANOMYTE® SuperAi, a Durable Anti-ice Coating December 4th, 2014

Biosenta Inc. Updates New Household Disinfectant Testing Results; It Kills 100% of a Broad Range of Deadly Molds, Fungi, Bacteria, and Viruses, Including Ebola and Enterovirus D68 November 20th, 2014

Possible Futures

Nanotechnology in Medical Devices Market is expected to reach $8.5 Billion by 2019 March 25th, 2015

Nanotechnology Enabled Drug Delivery to Influence Future Diagnosis and Treatments of Diseases March 21st, 2015

Nanocomposites Market Growth, Industry Outlook To 2020 by Grand View Research, Inc. March 21st, 2015

Nanotechnology Drug Delivery Market in the US 2012-2016 : Latest Report Available by Radiant Insights, Inc March 16th, 2015

Nanomedicine

Nanomedicine shines light on combined force of nanomedicine and regenerative medicine March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

Announcements

Rutgers, NIST physicists report technology with potential for sub-micron optical switches March 31st, 2015

Prototype 'nanoneedles' generate new blood vessels in mice: Scientists have developed tiny 'nanoneedles' that have successfully prompted parts of the body to generate new blood vessels, in a trial in mice March 31st, 2015

Super sensitive measurement of magnetic fields March 31st, 2015

Nanomedicine pioneer Mauro Ferrari at ETH Zurich March 31st, 2015

Nanobiotechnology

From tobacco to cyberwood March 31st, 2015

Wrapping carbon nanotubes in polymers enhances their performance: Scientists at Japan's Kyushu University say polymer-wrapped carbon nanotubes hold much promise in biotechnology and energy applications March 30th, 2015

'Atomic chicken-wire' is key to faster DNA sequencing March 30th, 2015

Designer's toolkit for dynamic DNA nanomachines: Arm-waving nanorobot signals new flexibility in DNA origami March 27th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE